IDP Pharma and BCN Peptides has entered a collaboration for the development of peptidomimetics. IDP Pharma will use its technology, IDP-Platform , to design peptidomimetics with target-specificity, intrinsic cell permeability properties and enhanced stability to target intra cellular proteins. BCN Peptide will optimize the synthesis and scale up the lead compounds.